Cinven has today completed the acquisition of Bioclinica, a global provider of clinical trial services and technology to contract research organisations (CROs) and pharmaceutical companies, for an undisclosed consideration.
Cinven's healthcare team identified Bioclinica as a compelling investment opportunity given the team’s strong track record in the clinical trials sector and direct experience through its investment in Medpace, a leading CRO business. Bioclinica operates in a number of high growth areas to improve the efficiency and productivity of clinical trials. Bioclinica benefits from structural factors including as growing clinical trial activity, increased outsourcing and the adoption of clinical software services.
Bioclinica represents the first investment from Cinven's sixth fund.